Navigation Links
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call
Date:7/23/2009

CARLSBAD, Calif., July 23 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

    What:       Isis Pharmaceuticals' Second Quarter 2009 Financial Results

    When:       Thursday, August 6, 2009 at 8:30 a.m. ET / 5:30 a.m. PT

    Where:      www.isispharm.com

    How:        Live on the Internet.  Simply log onto our Web site listed above.

    Contacts:   Kristina Lemonidis
                Director, Investor Relations
                (760) 603-2490

                Amy Blackley, Ph.D.
                Assistant Director, Corporate Communications
                (760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NHP Announces Second Quarter Earnings Release Date and Webcast/Conference Call
2. ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results
3. CorVel Announces Earnings Release Webcast
4. Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast
5. Smart Balance to Host Webcast/Conference Call on 2009 Second-Quarter Results
6. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
7. NBTY to Webcast Presentation at Oppenheimer 9th Annual Consumer, Gaming, Lodging & Leisure Conference; Announces Fiscal Third Quarter Preliminary Unaudited Net Sales Results
8. Boston Scientific to Webcast Conference Call Discussing Second Quarter Financial Results
9. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2009 Financial Results Conference Call
10. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
11. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: